Shots:
- In an engaging conversation with PharmaShots CXO Talks, Jared Kelly, CEO & Director of Oncolytics Biotech, shared insights from his experience leading corporate strategy at Ambrx and contributing to its $2B acquisition by Johnson & Johnson, offering a practical perspective on what makes biotech companies attractive acquisition targets.
- Kelly explained why successful biotech acquisitions depend on far more than promising clinical data, highlighting the importance of robust intellectual property, regulatory readiness, scalable manufacturing, strategic clinical positioning, and a clear path to commercialization as Oncolytics advances pelareorep across multiple oncology indications.
- Discussing the evolving oncology landscape, Kelly explored the growing role of combination therapies, the strategic focus on colorectal cancer, the impact of AI on drug development, and the critical factors that determine whether biotech partnerships and M&A deals ultimately succeed or fail.
What does it really take for a biotech company to become an attractive acquisition target?
In this episode of PharmaShots CXO Talks, Jared Kelly, CEO & Director of Oncolytics Biotech, shares an insider’s perspective shaped by years of experience in biotech transactions, corporate strategy, and business development.
Before joining Oncolytics, Kelly served as Head of Legal and Corporate Strategy at Ambrx, where he played a key role in the company’s landmark $2 billion acquisition by Johnson & Johnson. Drawing from that experience, he explains what pharmaceutical companies truly look for when evaluating potential acquisitions and why great clinical data alone is rarely enough.
As Oncolytics advances pelareorep across multiple oncology indications, Kelly discusses how the company is building toward what he calls the “Acquisition Zone” by strengthening its regulatory pathway, intellectual property portfolio, manufacturing capabilities, and clinical positioning.
In this conversation, you’ll discover:
- Lessons from Ambrx’s $2B acquisition by Johnson & Johnson
- What makes a biotech company acquisition-ready
- Why strong clinical data alone doesn’t close deals
- How Oncolytics is positioning itself for future partnership and acquisition opportunities
- Why colorectal cancer has emerged as a key strategic focus
- The future of combination therapies in oncology
- How AI is influencing drug development and decision-making
- The biggest reasons biotech deals succeed or fall apart
From billion-dollar M&A negotiations to advancing next-generation cancer immunotherapies, Kelly offers a rare behind-the-scenes look at the intersection of science, strategy, and deal-making in biotech.
Watch the full conversation below to hear firsthand how one executive helped navigate a $2 billion acquisition and how he’s applying those lessons to guide Oncolytics’ next chapter.
About Jared Kelly
Jared Kelly is an accomplished biotechnology executive and legal strategist with extensive experience across corporate law, capital markets, mergers & acquisitions, and business development within the life sciences industry. Prior to joining Oncolytics Biotech, he served as Head of Legal and Corporate Strategy at Ambrx, where he played a key role in the company’s $2 billion acquisition by Johnson & Johnson. Throughout his career, he has advised and led numerous strategic transactions for both public and private biotechnology companies.
At Oncolytics Biotech, Jared is focused on advancing the company’s clinical and corporate vision as it continues to develop pelareorep across multiple oncology indications. Under his leadership, the company is strengthening its position in immuno-oncology through strategic collaborations, clinical innovation, and a focused approach toward addressing challenging solid tumors.
